Clinical Trials Logo

Atrial Fibrillation clinical trials

View clinical trials related to Atrial Fibrillation.

Filter by:

NCT ID: NCT02770989 Terminated - Atrial Fibrillation Clinical Trials

Vimecon CAI Trial for the Interventional Treatment of Paroxysmal Atrial Fibrillation (AF)

CAI
Start date: March 2016
Phase: N/A
Study type: Interventional

This study is a prospective, non-randomized, single arm, multicenter, CE marking trial for patients with paroxysmal atrial fibrillation to undergo an ablation of the cardiac tissue near the PV.

NCT ID: NCT02762331 Terminated - Atrial Fibrillation Clinical Trials

High Dose Vitamin C in Cardiac Surgery Patients

Start date: January 1, 2017
Phase: Phase 1
Study type: Interventional

Coronary artery bypass grafting (CABG) is the most common procedure performed by cardiac surgeons. Post-operative atrial fibrillation (AF) is the most common adverse event following CABG, experienced in 20-50% of patients; the highest incidence of AF occurs by the third post-operative day. Reduction of AF by various drugs is moderately effective, but involves either rate control with beta blockers or rate conversion with amiodarone after the myocardial damage processes initiating AF have already occurred. Decreasing the incidence of post-operative AF, and hence the morbidity and mortality of high-risk CABG patients, could be more fruitfully approached by targeting the upstream combined processes of inflammation and coagulation activation induced by the surgical insult and associated ischemia-reperfusion (I/R). We propose that cell damage induced by oxidative stress and I/R injury could be prevented and/or inhibited by antioxidant supplementation. Specifically the investigators hypothesize that high-dose intravenous (IV) vitamin C supplementation will ameliorate ROS and therefore damp down upstream inflammatory processes, leading to a reduction of downstream adverse events with demonstrable links to inflammation processes, such as AF.

NCT ID: NCT02710669 Terminated - Atrial Fibrillation Clinical Trials

New Formulations of Propafenone to Treat Atrial Fibrillation

Start date: October 2016
Phase: Phase 1/Phase 2
Study type: Interventional

Propafenone is a currently used medicine to treat atrial fibrillation and is a mixture of two compounds, (R)-propafenone and (S)-propafenone. In this study, the investigators will randomize participants to (R)-propafenone, (S)-propafenone, or placebo.

NCT ID: NCT02703454 Terminated - Clinical trials for Paroxysmal Atrial Fibrillation

FIRM Ablation Versus Pulmonary Vein Isolation for the Treatment of Paroxysmal Atrial Fibrillation (PAF)

FIRMAP-AF
Start date: February 2016
Phase: N/A
Study type: Interventional

The study is designed as a prospective, multicenter, single-blind, randomized study to assess the safety and effectiveness of FIRM-guided radiofrequency (RF) ablation procedures for the treatment of symptomatic paroxysmal atrial fibrillation (PAF). The subjects will be blinded to study treatment for the duration of the study period.

NCT ID: NCT02686749 Terminated - Atrial Fibrillation Clinical Trials

Catheter Ablation vs. Medical Therapy in Congested Hearts With AF

CATCH-AF
Start date: June 2016
Phase: Phase 4
Study type: Interventional

This study is a multi-center, randomized, unblinded, clinical trial. The objective is to determine if catheter-based atrial fibrillation (AF) ablation is superior to medical treatment in patients with impaired left ventricular (LV) function who have been diagnosed with symptomatic AF within the past 12 months.

NCT ID: NCT02680483 Terminated - Atrial Fibrillation Clinical Trials

Atrial Fibrillation Registry in Jordan

JoAFR
Start date: August 2016
Phase:
Study type: Observational [Patient Registry]

Prospective registry of all new comers with Atrial fibrillation

NCT ID: NCT02668432 Terminated - Septic Shock Clinical Trials

Use of Amiodarone in Atrial Fibrillation Associated With Severe Sepsis or Septic Shock

Start date: May 2016
Phase: Phase 4
Study type: Interventional

Purpose/Objectives: Severe sepsis and septic shock are a common cause of new onset atrial fibrillation (NOAF) in the intensive care unit. Development of NOAF in this setting can prolong length of stay and increase mortality. Amiodarone is the most commonly used agent used in this setting to control rate and rhythm. However, limited data exist detailing appropriate dosing in this setting. The primary objective of this study is to evaluate two amiodarone dosing strategies, a full loading dose versus a partial loading dose, in patients with new-onset atrial fibrillation (AF) due to severe sepsis or septic shock to assess the mean heart rate every 6 hours after initiation of amiodarone infusion to day 7 or death. Research Design/Plan: Consecutive patients admitted to the medical or cardiac intensive care unit at University Hospital with NOAF in the setting of severe sepsis or septic shock will be screened for study inclusion. Data will be collected and stored using Microsoft Excel or Access and analyzed with JMP 12.0 and SPSS. Methods: Patients aged 18 years or older who develop new-onset atrial fibrillation in the setting of severe sepsis or septic shock and in whom the medical team deems appropriate to initiate amiodarone therapy in will be considered for study inclusion. Patients will receive intravenous (IV) and oral (PO) amiodarone, as per the standard of care. Patients will be randomized to a certain quantitative loading dose strategy; either a full loading dose (≥ 5g IV or ≥10g PO +/- 20%) or a partial loading dose (<4g IV or < 8g PO). Clinical Relevance: With intensive care unit length of stay (ICU LOS) and mortality being twice as high in NOAF with sepsis as compared to septic patients without NOAF, the investigators ultimately aim to identify a management strategy that may minimize this morbidity and mortality while also minimizing exposure to a drug that may cause serious adverse effects.

NCT ID: NCT02664311 Terminated - Atrial Fibrillation Clinical Trials

A Randomized Comparison of the Use of JET and Conventional Ventilation in Pulmonary Vein Isolation

Start date: February 2013
Phase: N/A
Study type: Interventional

This is a randomized prospective study comparing outcomes of pulmonary vein isolation using conventional and jet ventilation.

NCT ID: NCT02606552 Terminated - Clinical trials for Coronary Artery Disease

Safety and Efficacy of Left Atrial Appendage Closure Versus Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation Due to Complex Coronary Artery Disease

Start date: July 20, 2016
Phase: Phase 4
Study type: Interventional

Comparatively analyze the safety and validity of Amplazter Cardiac Plug (ACP) device-using percutaneous left atrial appendage closure, and the medical treatment with dabigatran plus aspirin or dabigatran plus clopidogrel after 3months triple therapy (Dabigatran plus DAPT (dual-antiplatelet therapy)) in patient with coronary artery disease treated with drug-eluting stent, accompanying atrial fibrillation. Total of 670 patients [left atrial appendage occlusion registry with 100 ACP/ 570 anti-coagulation registry: (285 Dabigatran plus aspirin) and (285 Dabigatran plus clopidogrel) therapy)] will be comparatively analyzed the safety and efficacy. Primary endpoints were a composite of death, non-fatal myocardial infarction, stroke, systemic embolism, and GUSTO bleeding (moderate to severe).

NCT ID: NCT02561897 Terminated - Atrial Fibrillation Clinical Trials

EdoxabaN or Warfarin Therapy In Device Procedures in Patients With Non-Valvular Atrial Fibrillation

ENTICED-AF
Start date: December 2015
Phase: Phase 4
Study type: Interventional

This is a prospective randomized comparative evaluation of Edoxaban and Warfarin for safety and efficacy in perioperative use in patients with non-valvular atrial fibrillation (AF) undergoing clinically indicated implantation or replacement of cardiovascular implantable electrical devices.The primary objective is to compare the rates of local and systemic bleeding in subjects randomized to Edoxaban compared to subjects randomized to continuous warfarin in within 30 days of cardiac rhythm device implant with concomitant non-valvular AF.